Claes Thulin leaving BioPhausia

BioPhausia's CEO Claes Thulin is leaving his post in order to pursue
entrepreneurial activities. The change of CEO is supported by the Board, which
has already started the process of recruiting a successor.


With Claes Thulin at the helm, BioPhausia evolved from a small research company
into a successful pharmaceutical company occupying a strong market position. "As
Claes leaves his position, with the full support of the Board, we would take
this opportunity to thank him for his sterling work during his years as CEO,"
says BioPhausia's Chairman of the Board Jan Rynning.

Mr. Thulin has offered to stay on as CEO until a successor is in place.
"After eight years as CEO I want to try something different, and intend to
pursue entrepreneurial activities in the area of pharmaceuticals," he explains.


For more information, please contact:

Jan Rynning, Chairman of the Board, tel. +46 (0)703510005
Claes Thulin, CEO, tel. +46 (0)8 4076430






[HUG#1384127]